Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be between 18-45 years old, inclusive~* Must be in general good health by volunteer history without any clinically significant systemic disease (including liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease)~* Must have regular menstrual cycles (minimum of 26 and maximum of 38 days)~* Must be at least 2 months since last pregnancy outcome and have had at least two spontaneous menses~* Must abstain from sexual activity and use of intravaginal products for 72 hours prior to the start of the single-dose phase and multi-dose phase, for at least one week following vaginal biopsies and for the duration of the study phases~* Willingness to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol~Exclusion Criteria:~* Currently pregnant or at risk for pregnancy (may be using Paragard® IUD, effective barrier method, female sterilization or abstinence, or be sexually active with a vasectomized partner)~* Currently breastfeeding or planning to breastfeed during the course of the study~* Use of any hormonal contraceptives within 30 days of enrollment~* Use of Depo-Provera within 120 days of enrollment History of abnormal Pap smear (by volunteer history) that has not been evaluated and treated, if indicated, according to standard guidelines~* Current vaginal or urinary tract infection~* Positive test for Neisseria gonorrhea or Chlamydia trachomatis at the time of screening~* Positive wet mount for Trichomonas vaginalis at the time of screening or enrollment~* Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for a sexually transmitted infection~* Current or past use of any anti-retroviral therapies including but not limited to systemic tenofovir (Viread®)~* Current or recent drug or alcohol abuse~* Current or anticipated use of drugs on a daily basis that may reduce renal function (e.g. acyclovir or ibuprofen) or liver function (e.g. tylenol)~* HIV positive at the time of screening~* Hepatitis B surface antigen (HBsAg) positive at the time of screening~* Grade 1 or higher serum chemistry or complete blood count abnormality in accordance with DAIDS toxicity table values~* Abnormal finding on laboratory or physical examination or a medical condition which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data~* Participation in any other research study in the 30 days prior to screening and/or plans to participate in any other research study during entire study duration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Twice daily (Type: OTHER): Tenofovir gel intravaginal twice daily for 14 days
- Once daily (Type: OTHER): Tenofovir gel intravaginal once daily for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete